Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Stu...

Por Mehta, Lahar, Umans, Kimberly, Ozen, Gulden, Robinson, Randy R., Elkins, Jacob
Publicado no Int J MS Care (2017)

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®

Por Ganguly, Bishu, Balasa, Balaji, Efros, Lyubov, Hinton, Paul R., Hartman, Stephen, Thakur, Archana, Xiong, Joanna M., Schmidt, Brian, Robinson, Randy R., Sornasse, Thierry, Vexler, Vladimir, Sheridan, James P.
Publicado no MAbs (2016)

High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, noninfectious uveitis

Por Yeh, Steven, Wroblewski, Keith, Buggage, Ronald, Li, Zhuqing, Kurup, Shree K., Sen, Hatice Nida, Dahr, Sam, Sran, Pushpa, Reed, George F., Robinson, Randy, Ragheb, Jack A., Waldmann, Thomas A, Nussenblatt, Robert B.
Publicado em 2008